By pooling international resources, the PALB2 Interest Group estimated that the relative risk of ovarian cancer and male breast cancer for PALB2 mutation carriers was 2.31 (95 % CI, 0.77–6.97; P = 0.18) and 8.30 (95 % CI, 0.77–88.56; P = 0.08) respectively [6]. This evidence concerns the gene PALB2 and ovarian carcinoma.